Generic GLP-1 weight-loss drugs have become significantly more affordable in India, but adoption remains slower than expected. Zerodha co-founder Nithin Kamath believes the issue isn't cost but long-term commitment, self-injections and conservative prescribing practices.
Generic GLP-1 weight-loss drugs have become significantly more affordable in India, but adoption remains slower than expected. Zerodha co-founder Nithin Kamath believes the issue isn't cost but long-term commitment, self-injections and conservative prescribing practices.
<iframe src="https://hindustansphere.com/embed/cluster/45678776de6bfb0ded3710e92dc86173c5c8de87" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Zerodha's Nithin Kamath says India's response to affordable weight-loss drugs is 'weird'. Here's why"></iframe>
Generic GLP-1 weight-loss drugs have become significantly more affordable in India, but adoption remains slower than expected. Zerodha co-founder Nithin Kamath believes the issue isn't cost but long-term commitment, self-injections and conservative prescribing practices.
